Shattuck Labs Jumps 5% as 2 Analysts Back SL-325 and See Upside to $18

2 articles · Updated · Yahoo Finance · Aug 24

Shattuck Labs rose nearly 5% on Monday after two analysts initiated bullish coverage, with Raymond James assigning a strong buy and an $18 price target versus the stock’s latest $7.90 close.
SL-325 drove the positive calls: the autoimmune and inflammatory disease candidate is being developed for two forms of inflammatory bowel disease, and analysts highlighted its novel receptor-targeting mechanism as a potential differentiator.
The drug has already advanced into Phase 2b testing after encouraging lab performance, giving investors a nearer-term development milestone to watch.
A Raymond James analyst estimated SL-325 could address at least a $20 billion market if it wins approval and takes share from existing treatments.